Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GlaxoSmithKline plc Vs AstraZeneca plc — Which Is The Better Bet For Income And Growth?
Motley Fool
Wednesday, February 12, 2014 - 9:19am
tags:
GSK, AstraZeneca, China
Ventrus Phase 3 trial of Diltiazem showed no significant difference to placebo
Yahoo/Fly on the Wall
Wednesday, February 12, 2014 - 9:17am
tags:
Ventrus Biosciences, Diltiazem, VEN 307
Antidepressant R&D Takes Another Hit with J&J
Motley Fool
Wednesday, February 12, 2014 - 9:15am
tags:
R&D, JNJ, antidepressants, Addex, ADX71149
Frantic Pace In Cancer Immunotherapy: Merck Vs. Bristol-Myers
Seeking Alpha
Wednesday, February 12, 2014 - 9:14am
tags:
cancer immunotherapy, Merck, Bristol-Myers Squibb, Amgen, Incyte, Pfizer, MK-3475, Ablynx, Yervoy
Ligand Beats Q4 Earnings
Yahoo/Zacks.com
Wednesday, February 12, 2014 - 9:12am
tags:
Ligand Pharmaceuticals, earnings
Narrower-than-Expected Loss at Seattle Genetics
Yahoo/Zacks.com
Wednesday, February 12, 2014 - 9:11am
tags:
Seattle Genetics, earnings
Gilead’s Milligan Says Hepatitis C Drug Attracts Payers
Bloomberg
Wednesday, February 12, 2014 - 9:11am
tags:
Gilead Sciences, hepatitus C, Sovaldi, insurance
Indian Regulators to Shadow U.S. FDA on Plant Inspections
Bloomberg
Wednesday, February 12, 2014 - 9:09am
tags:
India, inspections, FDA, drug manufacturing
GlaxoSmithKline R&D chief touts the future of 'electroceuticals'
Fierce Biotech
Tuesday, February 11, 2014 - 4:50pm
tags:
GSK, R&D, electroceuticals
3 Major Health-Care Deals You Need to Know About
Motley Fool
Tuesday, February 11, 2014 - 4:48pm
tags:
Forest Labs, Aptalis, Bristol-Myers Squibb, AstraZeneca, JNJ
Can drug makers find profit in collaboration?
Forbes
Tuesday, February 11, 2014 - 4:45pm
tags:
NIH, Bristol-Myers Squibb, Pfizer, GSK, Eli Lilly, Merck, Amgen
Big Pharma Diversification: A Winning Model or Recipe for Disaster?
Motley Fool
Tuesday, February 11, 2014 - 12:03pm
tags:
Big Pharma, diversification, Merck, Eli Lilly, AbbVie, Abbott Laboratories, Pfizer
4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14
BIOtechNOW
Tuesday, February 11, 2014 - 12:02pm
tags:
Alkermes, biotech, BIOCEO2014
What's Big Pharma's latest hot spot? The Middle East
Fierce Pharma
Tuesday, February 11, 2014 - 12:00pm
tags:
Middle East, Merck, Merck Serono, Sanofi, Novo Nordisk, Eli Lilly, Bayer
Cempra Antibiotic Candidate Clears Important Heart Safety Hurdle
TheStreet.com
Tuesday, February 11, 2014 - 11:55am
tags:
Cempra, antibiotics, Solithromycin
Zoetis Q4 Beats Estimates, But Guidance Hammers Stock
Investors.com
Tuesday, February 11, 2014 - 11:54am
tags:
earnings, Zoetis
Omeros Corp reports additional positive phase 1 clinical data for Oms824 for the treatment of cognitive disorders
Reuters
Tuesday, February 11, 2014 - 10:38am
tags:
Omeros, OMS824, cognitive disorders
Breakout Week for Biotech? Comment Now Follow Comments
Forbes
Tuesday, February 11, 2014 - 10:37am
tags:
Seattle Genetics, Regeneron
Zogenix in Final Preparations for Early March Market Launch
Yahoo
Tuesday, February 11, 2014 - 10:36am
tags:
Zogenix, Zohydro ER, painkillers
FDA to review possible heart risks with AstraZeneca's diabetes drug
Yahoo/Reuters
Tuesday, February 11, 2014 - 10:35am
tags:
FDA, AstraZeneca, diabetes, Onglyza

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.